Abzena upgraded its ADC GMP manufacturing facility

| By | Drug Manufacturing, GMP Standards
0
301

Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania (USA) site.

The facility is being equipped with state-of-the-art Sartorius and GE equipment for single use scale-up, manufacture and purification processes. The environmentally controlled suite will enable Abzena to produce antibody-drug conjugates (ADCs) for preclinical and early phase clinical studies. The suite is a significant part of Abzena’s integrated ADC capabilities for the design, development and manufacture of ADCs.

The facility and equipment verification and qualification for this ADC GMP manufacturing suite is currently underway, and scheduled for completion around the end of the second quarter of 2018.

Completion of the GMP ADC manufacturing suite construction marks a key point in Abzena’s programme to significantly expand the Group’s integrated ADC chemistry solutions. This ADC manufacturing suite complements the existing GMP manufacturing capability for the scale-up and manufacture of highly potent payload-linker constructs, and the upgrading and expansion of Abzena’s biologics process development and manufacturing capabilities in San Diego. The plans are on track for the initial relocation for Abzena’s biologics manufacturing process and analytical development groups into the new San Diego facility during April 2018.

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. Company has three principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

SOURCE: abzena
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.